Cefabol

Quick links to important sections

Cefabol

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefabol

Quick Facts

Property Description
Active ingredient Cefotaxime sodium
Form Lyophilized powder for injection (sterile)
Pharmacological class Beta-lactam antibiotic (3rd generation cephalosporin)
Common use Systemic bacterial infection control
Origin Semisynthetic

What Type of Antibiotic is Cefabol (Cefotaxime)?

Cefabol is a systemic, prescription-only (Rx) medicine defined by its active component, Cefotaxime. This substance is classified as a semisynthetic Beta-lactam antibiotic, belonging specifically to the 3rd generation cephalosporin class. This classification means the drug is engineered for broad-spectrum antimicrobial activity. Cefotaxime is an antibiotic used to eliminate susceptible bacteria. Unlike older generations of cephalosporins, Cefotaxime's specific chemical structure provides improved stability against certain bacterial enzymes, providing an extended antimicrobial scope.


Composition and How Cefabol is Prepared for Use

This medication is composed of Cefotaxime sodium and is supplied in a stable form: a lyophilized powder for injection contained within a sterile vial. This powder ensures the chemical integrity of the active ingredient, a formulation used for agents requiring high potency. For clinical administration, this sterile powder is not ready-to-use but must first be reconstituted with a sterile solvent to create an aqueous solution for injection. This specific preparation is required because Cefabol is intended for parenteral administration—that is, delivery directly into the body via injection—to ensure absorption into the bloodstream for treating systemic infections.


What is the General Therapeutic Purpose of this Class of Drug?

The general therapeutic purpose of Cefabol is to function as a broad-reaching tool for overcoming serious bacterial infections throughout the body. The fundamental action of this 3rd generation cephalosporin is achieved by interfering with the process of bacterial cell wall synthesis. By disrupting the vital structure that bacteria need to survive, Cefabol brings about the death of the microorganism, assisting the patient's immune system in resolving the infection.

Regulatory References

  1. NIH/MedlinePlus: Cefotaxime Injection
  2. WHO Essential Medicines List: Cefotaxime

What side effects are possible with Cefabol?

Possible Side Effects and Safety Information

The following safety information regarding Cefabol (Cefotaxime) is based exclusively on official government regulatory documents, detailing documented adverse reactions, frequency classifications, and necessary safety constraints.

Documented Adverse Reactions and Frequencies

Adverse reactions are classified by the affected System Organ Class (SOC) and their frequency, which ranges from Very Common to Not Known, based on regulatory standards.

Frequency Classification Examples of Documented Effects
Very Common (ge 1/10) Pain at the injection site (IM administration)
Uncommon (ge 1/1,000 to <1/100) Leukopenia, Thrombocytopenia, Convulsions, Diarrhoea, Increased liver enzymes, Rash, Pruritus, Fever
Not Known Anaphylactic shock, Pseudomembranous colitis, Severe skin reactions (SJS/TEN), Encephalopathy, Agranulocytosis, Arrhythmia

Serious Adverse Reactions and Safety Constraints

Official regulatory sources highlight specific, clinically significant risks and safety considerations:

  • Serious Reactions: Documented severe events include Anaphylactic Shock, severe skin reactions like Stevens-Johnson Syndrome (SJS), Pseudomembranous Colitis, and potentially fatal Arrhythmia linked to rapid intravenous administration.
  • Neurotoxicity: High doses, particularly in patients with renal insufficiency, carry an increased risk of encephalopathy and convulsions.
  • Duration-Related Safety: For treatment courses lasting longer than 7 to 10 days, the potential for leucopenia or agranulocytosis is noted, requiring monitoring.
  • Cross-Allergy Caution: Regulatory information notes a constraint related to possible cross-allergy in individuals sensitive to penicillins.
  • Testing Interference: The medication is documented to potentially cause a false positive Coombs test and interfere with certain urinary glucose tests.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose manifestations for Cefabol (Cefotaxime) as primarily affecting the Central Nervous System (CNS). Documented presentations include convulsions, seizure, myoclonia, and reversible encephalopathy.

Overdose situations carry a risk of severe outcomes, including impairment of consciousness and the potential for life-threatening arrhythmia associated with overly rapid intravenous administration. High dosages have been linked to severe events, including fatality.

Required Emergency Actions

In the event of suspected overdose, individuals are formally mandated to seek emergency medical attention immediately. Cefotaxime must be discontinued immediately.

No specific antidote exists. Management is therefore symptomatic and supportive, including measures to accelerate elimination. Procedures such as haemodialysis or peritoneal dialysis are noted as methods to reduce plasma levels.

Population Considerations

The risk of severe CNS effects, particularly encephalopathy and seizures, is formally documented to be increased in patients with severely restricted kidney function if the administered dose is not appropriately reduced.

Therapeutic Uses of Cefabol

What Cefabol Treats: Main Uses and Benefits

Cefabol (Cefotaxime) is used to address a wide array of serious, acute bacterial infections throughout the body, providing therapeutic support when infections are pronounced and create noticeable physiological strain. The medication is indicated for the treatment of susceptible microorganisms to reduce the impact of the infection on the body.

The medication is commonly used in therapeutic contexts involving critical systemic infections like sepsis and bacterial meningitis; complicated deep-seated infections such as severe pneumonia, peritonitis (abdominal infections), and infections of the bone and joints; and for pre-surgical infection prevention (prophylaxis). The use of this agent in these scenarios supports control over opportunistic or resistant bacteria and assists with managing acute symptoms like high fever, chills, and localized pain by addressing the underlying bacterial cause.

This therapeutic support may assist with stabilizing the patient and contributes to a more manageable clinical course by reducing the physiological distress and discomfort associated with systemic or localized bacterial pathology.


Quick Fact: Therapeutic Context

Symptom Domain Conditions Managed Patient Benefit
Systemic/Neurological Sepsis, Meningitis Supports clinical stability and management of severe fever and chills
Organ-Specific Pneumonia, Peritonitis, Bone Infections Supports resolution of the infection, reducing localized pain
Clinical Context Hospital-acquired infections, Surgical Prophylaxis Helps mitigate risk of complications and supports infection control

Eligibility and Restrictions for Use

Cefabol (Cefotaxime) eligibility is defined by official regulatory criteria, primarily focusing on patient allergy status and organ function.

Contraindications

Use of Cefabol is strictly contraindicated for any patient with a known history of hypersensitivity to Cefotaxime, any other cephalosporin antibiotic, or a severe, immediate-type allergic reaction to any beta-lactam drug (e.g., penicillin). The medicine must not be used intravenously if the formulation contains Lidocaine, nor in patients with specific cardiac conditions (e.g., severe heart failure).


Restricted or Conditional Use

Population/Condition Regulatory Requirement (Caution/Restriction)
Renal Impairment Caution required; dosage adjustment and monitoring are mandated, particularly in severe cases (creatinine clearance <20 mL/ min) to prevent neurotoxicity [Source 1.1, 2.4].
Age Groups Approved for all ages. Infants under 30 months are excluded from using Lidocaine-containing formulations [Source 2.4]. Older adults require caution due to potential age-related kidney decline [Source 1.1].
Pregnancy/Lactation FDA Category B. Use in pregnancy should be restricted to cases where it is clearly needed due to a lack of established safety data. Caution is advised during breastfeeding [Source 1.4, 2.2].

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns strictly based on authoritative government drug labels.

Interaction Type Interacting Substance(s) Officially Documented Outcome
Pharmacokinetic (Clearance) Probenecid (Uricosuric agent) Competition for renal tubular secretion pathways. Results in increased Cefabol plasma exposure and reduced clearance, raising drug levels.
Pharmacodynamic (Toxicity) Aminoglycoside antibiotics (e.g., Gentamicin) Additive nephrotoxicity, documented as a potential increase in the risk of kidney-related toxicity.
Pharmacodynamic (Toxicity) Potent Diuretics (e.g., Furosemide) May potentiate the nephrotoxic effects associated with other nephrotoxic drugs.
Administration Restriction Lignocaine (as a diluent) Formally contraindicated for intravenous use and for intramuscular use in specific patient populations, such as infants under 30 months.

Procedural and Compatibility Constraints

Physical Incompatibility: Cefabol must not be physically mixed with Aminoglycoside antibiotics in the same syringe or infusion fluid due to documented physical or chemical incompatibility, even when co-administration is intended.

Antagonistic Effect: Official documentation notes an observed antagonistic effect in vitro when Cefabol is combined with certain bacteriostatic antibiotics, though the clinical significance is not always established.

Population-Specific Caution: The official drug label notes that caution is required with the co-administration of Probenecid and other nephrotoxic drugs in patients with renal impairment, where altered clearance may necessitate specific consideration.

Mechanism of Action

How Cefabol Works

Cefabol (Cefotaxime) is a bactericidal agent that operates through specific molecular actions directed at the structures of susceptible bacteria.


1. Direct Targeting of Bacterial Cell Wall Synthesis

The primary mechanism involves the irreversible covalent inhibition of bacterial Penicillin-Binding Proteins (PBPs), a group of enzymes essential for forming the structural layer of the bacterial cell wall. Its mechanism is specific to microbial components. By binding permanently to these enzymes—specifically the transpeptidases—Cefabol halts the process of peptidoglycan cross-linking, which is the final step in synthesizing a stable cell wall. This molecular action results in the bacterial cell being unable to maintain its structural defenses.


2. Cascade Leading to Cell Lysis (Bacterial Destruction)

The disruption of cell wall assembly initiates a rapid mechanistic cascade. The compromised cell wall, combined with the activation of the bacteria's own latent degradative enzymes (autolysins), fails to withstand the internal osmotic pressure. This leads to the rupture and dissolution of the bacterial cell (lysis), resulting in the bactericidal effect and physical removal of the susceptible microbial mass.


3. Mechanistic Constraints: Enzyme-Mediated Resistance

A key constraint on Cefabol's mechanism is the bacterial production of beta-lactamase enzymes. These enzymes act as a direct counter-mechanism by chemically inactivating the drug. They hydrolyze the beta-lactam ring, preventing Cefabol from reaching and binding to its PBP targets. This biological defense mechanism results in the hydrolysis of Cefabol, preventing the inhibition cascade.

Dosage and Administration Information

How Cefabol (Cefotaxime) is Used

Cefabol is a prescription-only medicine supplied as a lyophilized sterile powder for injection. The administration of this agent is characterized by specific parameters regarding delivery and dosing, which are determined by the severity of the infection and the patient's physiological condition.

Administration Route and Preparation

Cefabol is intended for parenteral administration, delivered either intravenously (IV)—typically as a slow bolus over 3 to 5 minutes or as an intermittent infusion—or by deep intramuscular (IM) injection. Before administration, the sterile powder requires reconstitution using a compatible sterile solvent. For IM injections, reconstitution with a 1% lidocaine solution is a recognized method, though lidocaine is not used for the IV route.

Standard Dosing Patterns

The adult daily dose typically ranges from 2 g up to a maximum of 12 g. The frequency of administration is adjusted based on the severity of the infection, ranging from every 12 hours (q12h) for uncomplicated cases to every 4 hours (q4h) for severe conditions. The duration of therapy varies, often continuing for **3 to 4 days after clinical symptoms have resolved.

Population-Specific Adjustment

Clinical guidance exists for dose modification in the presence of renal impairment. For adult patients with severe renal failure (creatinine clearance ≤ 5 mL/min), the maintenance dose involves a 50% reduction following the initial loading dose to account for the altered clearance of the drug. Standard adjustments are generally not required for older adults with normal renal function for their age.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Cefabol (Cefotaxime)


Evidence for Use in Severe Systemic Infections (Sepsis/Septicemia)

The evidence base for Cefabol in treating severe systemic infections, such as those that involve the spread of bacteria through the bloodstream (sepsis), includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted during periods of increased symptom activity and focused on critically ill patients, including adults and very young children, who were experiencing physiological strain. Researchers measured key outcomes such as the rate at which the infection was cleared (bacteriological eradication) and overall rates of clinical resolution. Findings describe patterns observed in the studies, including those related to clinical resolution and survival metrics.

Evidence for Use in Bacterial Meningitis

Cefabol was evaluated in comparative trials and systematic reviews for the treatment of bacterial meningitis. A large part of the research was evaluated in infants and children, as well as adult cohorts. These studies monitored patient responses over defined time intervals, including monitoring for neurological or hearing complications (sequelae) in patients months after the acute phase. Findings describe patterns observed in these studies regarding clinical resolution and report how the condition evolved in the observed populations.

Long-Term Follow-up and Research Gaps

The majority of Cefabol research focuses on acute infection control; consequently, there is limited information for long-term outcomes or durability of effect. Follow-up durations were limited in most primary clinical trials, meaning the research provides context but not individual predictions regarding the recurrence of infection or patient health status months or years after the treatment course is complete. Evidence is still emerging and often mixed when examining the impact of Cefabol use on how bacteria develop resistance—the way bacteria change over time to potentially evade treatment. These data are still emerging and certainty remains low in these specialized areas of public health research.

Key Studies & References

  1. Pharmacokinetics and Pharmacodynamics of Cefotaxime in Critically Ill Patients: A Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Cefabol (FAQ)

Q: What kind of infections (e.g., skin, lung, urinary) is Cefabol most effective against?

A: Official information states that Cefabol is indicated for the treatment of various serious infections. These indications include infections of the lower respiratory tract, skin and skin structure, bone and joints, and the urinary tract. It is also indicated for severe systemic infections such as sepsis and meningitis caused by susceptible organisms.


Q: Is Cefabol effective against Methicillin-Resistant S. aureus (MRSA)?

A: Regulatory information indicates Cefabol is used for infections caused by susceptible strains of Staphylococcus aureus, including those that produce penicillinase. Official prescribing information does not specifically list efficacy against Methicillin-Resistant S. aureus (MRSA). The drug is used only against organisms confirmed or strongly suspected to be susceptible to Cefabol.


Q: What are the signs of a non-severe allergic reaction to Cefabol that warrant a call to a doctor?

A: Hypersensitivity reactions such as rash, pruritus (itching), or fever have been reported. While severe skin reactions require immediate medical attention, patients are advised to report any persistent or worsening rash or itching to a healthcare professional. These symptoms should be reviewed by a healthcare provider.


Q: Can Cefabol interact with common blood thinners or gout medications?

A: Yes, regulatory documents note that Cefabol has interactions with certain other medications. It can interact with Probenecid, a medication often used for gout. The official drug label also indicates that Cefabol can interact with certain types of blood thinners, such as warfarin, and warrants professional monitoring.


Q: What should be monitored by a doctor during a long-term treatment course with Cefabol?

A: For treatment lasting longer than 7 to 10 days, standard medical practice may include monitoring the patient's blood white cell count to check for leukopenia or neutropenia. Discontinuation of treatment may be considered if a low white cell count is observed. Kidney function may also be monitored if Cefabol is given with other potentially kidney-toxic drugs.


Q: Can Cefabol cause confusion or dizziness?

A: Official product information notes that at very high doses, especially in patients with pre-existing kidney impairment, there is an increased risk of central nervous system effects. This risk is associated with effects such as reversible encephalopathy, which has included reports of symptoms like confusion or convulsions.


Q: Does Cefabol target Gram-positive or Gram-negative bacteria more effectively?

A: Cefabol is classified as a broad-spectrum antibiotic. Official pharmacological data indicates that it possesses an extended spectrum and increased potency against Gram-negative bacteria, such as Haemophilus influenzae. It maintains moderate activity against some Gram-positive bacteria.


Q: Is a rash from Cefabol always a sign of a severe allergy?

A: No, a rash is listed as an uncommon adverse effect and is not always a sign of a severe allergic reaction. However, rare but severe allergic events like anaphylaxis or serious skin syndromes have been reported. Any new or worsening rash warrants review by a healthcare professional.


Q: Is Cefabol considered a 'strong' antibiotic compared to penicillin?

A: Cefabol belongs to the third-generation cephalosporin class of antibiotics. Regulatory documents classify this generation as having an extended spectrum of antimicrobial activity and improved stability against certain bacterial enzymes when compared to penicillin and earlier-generation cephalosporins.


Q: What are the specific concerns for older adults (65+) when using Cefabol?

A: Official product information advises caution when Cefabol is administered to older adults. This is primarily due to the greater likelihood of age-related decline in kidney function. Impaired kidney function may necessitate dosage adjustment and monitoring to prevent the drug and its active metabolite from accumulating.


Q: What is Cefabol primarily prescribed for, besides general infection treatment?

A: Beyond general infection control, Cefabol is indicated for serious systemic issues. These indications include conditions such as sepsis (blood poisoning), bacterial meningitis (infection of the brain and spinal cord lining), and certain bone and joint infections.


Q: Is Cefabol used more often to treat infections or to prevent them?

A: Cefabol is indicated for the treatment of severe, established infections across multiple body systems. Regulatory information also notes its use for perioperative prophylaxis, which means preventing infection during or shortly after certain surgical procedures.


Q: Why might a metallic or sour taste in the mouth happen with Cefabol injections?

A: A change in the sense of taste, including an unusual, bad, or unpleasant aftertaste, has been reported as a rare side effect of Cefabol treatment. This sensation may be perceived as a metallic or sour taste by the patient.


Q: Is a headache a common side effect of Cefabol treatment?

A: While not listed among the most frequent adverse reactions, headache has been reported in post-marketing or other reports related to Cefabol. This side effect is generally classified as rare or infrequent.


Q: How long does Cefabol stay in the system after the last dose?

A: Pharmacokinetic data from regulatory sources show that the half-life of Cefabol (cefotaxime) is approximately one hour for the parent drug. Its active metabolite has a slightly longer half-life of about 1 to 1.5 hours. The drug is eliminated from the body based on this half-life.


Q: Are there any specific supplements or vitamins that should be avoided while on Cefabol?

A: Patients are advised to inform their doctor about all products they are taking. This includes all nonprescription medications, vitamins, nutritional supplements, and herbal products, as these may have potential interactions with Cefabol.


Q: Can Cefabol affect blood sugar levels, especially for someone with diabetes?

A: The official drug label requires that a patient’s medical history, including whether they have diabetes, be carefully reviewed before treatment. This indicates that diabetes is a condition that necessitates review and individualized assessment during Cefabol therapy.


Q: Can Cefabol be used for bacterial infections in the bones or joints?

A: Yes, Cefabol is specifically indicated in official regulatory documents for the treatment of bone and/or joint infections that are caused by susceptible strains of bacteria.


Q: What is the risk of having a seizure while being treated with Cefabol?

A: The risk of having a seizure (convulsions) is listed as an uncommon side effect. This risk is notably increased at very high doses, especially in patients with pre-existing renal insufficiency (kidney problems), due to the potential for the drug to affect the central nervous system.


Q: Is it normal to experience pain or swelling at the Cefabol injection site?

A: Yes, pain at the injection site is listed as a Very Common side effect, particularly when the drug is administered intramuscularly (IM). Swelling and irritation have also been reported at the site where the injection is given.


Q: How does the mechanism of Cefabol differ from non-cephalosporin antibiotics?

A: Cefabol is a beta-lactam antibiotic, and its mechanism is characteristic of this class. It works by inhibiting bacterial cell wall synthesis through binding to Penicillin-Binding Proteins (PBPs). This is a primary feature that distinguishes it from antibiotics in entirely different classes that target bacterial components like DNA or protein synthesis.


Q: Can Cefabol cause temporary changes in urination frequency or amount?

A: Changes in urination patterns, such as a temporary decreased urine output or an increased urge to urinate, have been reported as rare side effects in patients receiving Cefabol.


Q: Are there different forms of Cefabol (powder, liquid, pre-mixed) and what are they used for?

A: Cefabol is supplied as a lyophilized sterile powder in a vial. For administration, this powder must be reconstituted with sterile water or other compatible solutions to create a liquid for injection or infusion. It is not supplied as a pre-mixed liquid.


Q: Why is it noted that Cefabol does penetrate the central nervous system?

A: Regulatory documents state that Cefabol does penetrate the cerebrospinal fluid (CSF), especially when the protective membrane surrounding the brain and spinal cord (the meninges) is inflamed. This property is why it is effective and indicated for the treatment of severe infections like bacterial meningitis.


Q: Are there specific symptoms that signal a rare but serious liver or kidney problem from Cefabol?

A: Serious adverse effects on the liver or kidneys can sometimes occur. Symptoms that signal a potential problem include dark urine or a yellowing of the skin or the whites of the eyes (jaundice). These symptoms warrant immediate review by a healthcare provider.


Q: Can Cefabol affect the effectiveness of hormonal birth control pills or patches?

A: Official information indicates that Cefabol injection may decrease the effectiveness of hormonal contraceptives. This includes birth control pills, patches, rings, and injections. The need for alternative or additional non-hormonal birth control methods warrants discussion with a healthcare provider.


Q: Does Cefabol interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Regulatory information advises caution when Cefabol is co-administered with other drugs that can cause kidney toxicity. This includes Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as ibuprofen, and co-administration warrants professional review.


Q: Can Cefabol cause a yeast infection (thrush) in the mouth or genital area?

A: Official product information states that the use of antibiotics, including Cefabol, may lead to the overgrowth of non-susceptible organisms, such as fungi. This can result in secondary infections, including yeast infections (candidiasis or thrush) in the mouth or genital area.


Q: Is it normal for the reconstituted Cefabol solution to appear pale yellow?

A: The sterile powder is typically white or slightly yellowish, and the official preparation instructions note that the reconstituted solutions may change to a light yellow color. It is important that only clear solutions free from particles are used for administration.


Q: What does it mean that Cefabol is sometimes used for 'perioperative prophylaxis'?

A: Perioperative prophylaxis is an approved indication for Cefabol. This means the antibiotic is administered before or during a surgical procedure to prevent the development of a surgical site infection, rather than to treat an infection that is already established.


Q: Why is it advised to avoid taking diarrhea medicine when experiencing diarrhea from Cefabol?

A: Official warnings state that if diarrhea occurs, particularly if it is severe or persistent, it could be a sign of Clostridium difficile-associated diarrhea (CDAD). It is advised that medicinal products that inhibit peristalsis (or slow the movement of the gut) should generally not be used in this case, as they can potentially worsen this condition.

How should Cefabol be stored and disposed of?

How to Store and Dispose of Cefabol?

Cefabol (cefotaxime sodium) is supplied as a sterile lyophilized powder, and its storage and disposal must strictly adhere to regulatory requirements to maintain integrity and ensure proper handling.

Official Storage Requirements

Condition Requirement (Unopened Vial)
Temperature Store at Controlled Room Temperature, not above 25°C (77°F).
Protection Keep the vial in its original outer carton to protect from light.
Child Safety KEEP OUT OF REACH OF CHILDREN is a mandatory labeling instruction.

In-Use Stability and Disposal Rules

Once reconstituted, the solution is intended for immediate use. If a delay is necessary, the product may be stored for a maximum of 24 hours when refrigerated (2 C to 8 C). The product is a single-use vial; any unused portion must be immediately discarded. Disposal of the expired or unused medicine and waste materials must be carried out in accordance with local regulatory requirements, and it must not be discharged into drains or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefabol found in:

A-Z Index: